Patents by Inventor Haoxi HUANG

Haoxi HUANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF
    Publication number: 20230044722
    Abstract: Disclosed are a macrocyclic fluorine-containing heterocyclic derivative of formula (I), a preparation method thereof, and a use thereof in treatment of TRK kinase-mediated diseases.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 9, 2023
    Inventors: Anle YANG, Haoxi HUANG, Tonghui CHEN, Jie LIANG, Dewei ZHANG, Jingen DENG, Hongbo LI, Junjie PU
  • Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof
    Patent number: 10793576
    Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: October 6, 2020
    Assignees: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD., CHENGDU HIGHBRED PHARMACEUTICAL CO., LTD.
    Inventors: Yingfu Li, Haoxi Huang, Guanfeng Liu, Tonghui Chen, Junfeng Ren, Zhonghai Su
  • Hydrobromide of benzodiazepine derivative, preparation method and use thereof
    Patent number: 10618904
    Abstract: The present invention provides a hydrobromide of methyl 3-[(4s)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazol[1,2-a][1,4]benzodiazepine-4-yl] propionate and its related crystal forms, preparation method and use thereof. The hydrobromide has excellent solubility (>100 mg/ml), which is significantly superior to other currently commercially available or developed salt products, and is especially suitable for the preparation of injections, has relatively good stability in various crystal forms, and has good practical value and market prospects.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: April 14, 2020
    Assignee: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.
    Inventors: Haoxi Huang, Guoqing Zhuo, Guoning Shang, Zhen Liang, Ting Chu, Cuicui Chen, Ming Luo, Yingfu Li, Zhonghai Su
  • COMPOUND USED AS BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20190315758
    Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.
    Type: Application
    Filed: February 20, 2017
    Publication date: October 17, 2019
    Inventors: Yingfu Li, Haoxi Huang, Guanfeng Liu, Tonghui Chen, Junfeng Ren, Zhonghai Su
  • HYDROBROMIDE OF BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
    Publication number: 20190308981
    Abstract: The present invention provides a hydrobromide of methyl 3-[(4s)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazol[1,2-a][1,4]benzodiazepine-4-yl] propionate and its related crystal forms, preparation method and use thereof. The hydrobromide has excellent solubility (>100 mg/ml), which is significantly superior to other currently commercially available or developed salt products, and is especially suitable for the preparation of injections, has relatively good stability in various crystal forms, and has good practical value and market prospects.
    Type: Application
    Filed: December 13, 2016
    Publication date: October 10, 2019
    Applicant: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.
    Inventors: Haoxi HUANG, Guoqing ZHUO, Guoning SHANG, Zhen LIANG, Ting CHU, Cuicui CHEN, Ming LUO, Yingfu LI, Zhonghai SU